Clinical Trials Using Zoledronic Acid
Clinical trials are research studies that involve people. The clinical trials on this list are studying Zoledronic Acid. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor.
Location: 3 locations
Zoledronic Acid before and after Surgery in Treating Patients with Grade I-III Chondrosarcoma
This phase Ib trial studies the side effects and how well zoledronic acid works before and after surgery in treating patients with grade I-III chondrosarcoma. Zoledronic acid may be an effective treatment for chondrosarcoma and cause less severe side effects.
Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa
Hypofractionated Stereotactic Body Radiation Therapy and Fluorouracil or Capecitabine with or without Zoledronic Acid in Treating Patients with Locally Advanced Pancreatic Cancer
This randomized phase II trial studies how well hypofractionated stereotactic body radiation therapy and fluorouracil or capecitabine with or without zoledronic acid work in treating patients with pancreatic cancer that has spread from where it started to nearby tissue or lymph nodes. Hypofractionated stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Drugs used in chemotherapy, such as fluorouracil and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Zoledronic acid is used in cancer patients to reduce cancer symptoms and may make tumor cells more sensitive to radiation. Giving hypofractionated stereotactic body radiation therapy and fluorouracil or capecitabine with or without zoledronic acid may work better in treating patients with pancreatic cancer.
Location: University of Nebraska Medical Center, Omaha, Nebraska
Genetically Modified Donor Stem Cell Transplant Followed by Zoledronic Acid in Treating Younger Patients with Relapsed / Refractory Hematologic Malignancies or High Risk Solid Tumors
This phase I trial studies the side effects of zoledronic acid given after genetically modified donor stem cell transplant in treating younger patients with hematologic malignancies or high risk tumors that have returned after a period of improvement (relapsed) or do not respond to treatment (refractory). Giving chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When healthy stem cells from a donor that have been genetically modified are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Giving mycophenolate mofetil and tacrolimus after the transplant may stop this from happening. Giving zoledronic acid after the transplant may help strengthen the immune system and make the immune cells work better.
Location: University of Wisconsin Hospital and Clinics, Madison, Wisconsin
Response of Bone Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers with Actionable Driver Mutations
This trial studies the response of bone metastasis to tyrosine kinase inhibitors in non-small cell lung cancers with actionable driver mutations. This study plans to learn more about how different drug regimens for advanced non-small cell lung cancer and bone metastases affect bone turnover markers and the need for additional drugs to treat bone metastases.
Location: University of Colorado Hospital, Aurora, Colorado